PMEL and neoplasm: In a proof of concept, we initially tested in J-76 the option to coexpress a tumor-reactive scTCR gp100 + Cα and a CMV-specific dcTCR pp65, the latter one which mimics the endogenous TCR pp65 in a CMV-specific T-cell population isolated from a CMV-positive donor.